Home > Expanded Access > Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Pfizer

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Official Title: 
A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
Brief Summary: 
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.
Detailed Description: 

Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181037 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.

Approved for marketing
Carcinoma, Renal Cell

Drug: Sutent
Sutent, 25, 37.5. or 50 mg daily

Eligibility Criteria: 

Inclusion Criteria:

- renal cell carcinoma that is not amendable to standard therapy with curative intent

Exclusion Criteria:

- current treatment in another therapeutic clinical trial

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 18 Years
Countries: 
Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Ecuador, Egypt, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Korea, Republic of, Lebanon, Malaysia, Mexico, Netherlands, Norway, Panama, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Venezuela
Locations: 

Pfizer Investigational Site
Scottsdale, Arizona, 85260

Pfizer Investigational Site
San Francisco, California, 94115-2378

Pfizer Investigational Site
San Francisco, California, 94115

Pfizer Investigational Site
Aurora, Colorado, 80040-0510

Pfizer Investigational Site
Norwalk, Connecticut, 06856

Pfizer Investigational Site
Miami, Florida, 33176

Pfizer Investigational Site
Ocala, Florida, 34474

Pfizer Investigational Site
Tampa, Florida, 33612

Pfizer Investigational Site
Atlanta, Georgia, 30309

Pfizer Investigational Site
Maywood, Illinois, 60153

Pfizer Investigational Site
Indianapolis, Indiana, 46260-2082

Pfizer Investigational Site
Council Bluffs, Iowa, 51503

Pfizer Investigational Site
Covington, Louisiana, 70433

Pfizer Investigational Site
Gretna, Louisiana, 70056

Pfizer Investigational Site
Marrero, Louisiana, 70072

Pfizer Investigational Site
Metairie, Louisiana, 70002

Pfizer Investigational Site
Metairie, Louisiana, 70006

Pfizer Investigational Site
New Orleans, Louisiana, 70115

Pfizer Investigational Site
Baltimore, Maryland, 21287

Pfizer Investigational Site
Boston, Massachusetts, 02114

Pfizer Investigational Site
Boston, Massachusetts, 02115

Pfizer Investigational Site
Boston, Massachusetts, 02215

Pfizer Investigational Site
Detroit, Michigan, 48201

Pfizer Investigational Site
Minneapolis, Minnesota, 55455

Pfizer Investigational Site
Southaven, Mississippi, 38671

Pfizer Investigational Site
Tupelo, Mississippi, 38801

Pfizer Investigational Site
Columbia, Missouri, 65201

Pfizer Investigational Site
Columbia, Missouri, 65203

Pfizer Investigational Site
Omaha, Nebraska, 68198-7680

Pfizer Investigational Site
Bronx, New York, 10466

Pfizer Investigational Site
New York, New York, 10021

Pfizer Investigational Site
New York, New York, 10022

Pfizer Investigational Site
Durham, North Carolina, 27710

Pfizer Investigational Site
Cleveland, Ohio, 44195

Pfizer Investigational Site
Norman, Oklahoma, 73071

Pfizer Investigational Site
Oklahoma City, Oklahoma, 73102

Pfizer Investigational Site
Oklahoma City, Oklahoma, 73109

Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112

Pfizer Investigational Site
Oklahoma City, Oklahoma, 73120

Pfizer Investigational Site
Tulsa, Oklahoma, 74104

Pfizer Investigational Site
Tulsa, Oklahoma, 74136-1902

Pfizer Investigational Site
Portland, Oregon, 97210

Pfizer Investigational Site
Portland, Oregon, 97227

Pfizer Investigational Site
Hershey, Pennsylvania, 17033-0850

Pfizer Investigational Site
Memphis, Tennessee, 38104

Pfizer Investigational Site
Memphis, Tennessee, 38120

Pfizer Investigational Site
Dallas, Texas, 75246

Pfizer Investigational Site
Salt Lake City, Utah, 84112

Pfizer Investigational Site
Seattle, Washington, 98104

Pfizer Investigational Site
Seattle, Washington, 98109

Pfizer Investigational Site
Seattle, Washington, 98122

Pfizer Investigational Site
Seattle, Washington, 98124

Pfizer Investigational Site
Madison, Wisconsin, 53792

Pfizer CT.gov Call Center
Study Director
Pfizer

EA Number: 
MeSH Terms: 
Carcinoma, Carcinoma, Renal Cell, Sunitinib
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.